Malignant melanoma cells show high aggressiveness and metastatic potential. Tumor cells as they become more metastatic, gradually lose their dependence on both adhesion and serum. Thus, in the process of tumor progression cells undergo series of changes that allow them to adapt to dierent tissue milieu. This implies that during this process, points on the integrin pathway may become constitutively activated. In the present study we investigated the possible role of FAK, being one of the key members of the integrin-signaling pathway, in the multistep progression towards a malignant phenotype in human melanoma. In our study we show that in melanoma cells there is neither an increase in the amount of FAK nor in its phosphorylation capacity, but rather in its levels of constitutive activation. Indeed, in all melanoma cells tested and not in nevus and neuroblastoma cells, we observed various degrees of constitutive activation of FAK. Our results also suggest that FAK constitutive activation is regulated at least in part by the cytoskeleton, implying that steps along the integrin signaling pathway involving FAK could be among the oncogenic mechanisms that operate in melanoma and may account for the highly aggressive, anchorage independent phenotype of this tumor.
Introduction
Metastatic spread of malignant melanoma is the main cause of morbidity and mortality of this cutaneous malignancy. Metastatic spread is a complex process involving a series of sequential events including, among other, detachment of tumor cells from the primary site, invasion through the basement membrane and the underlying extracellular matrix (ECM), intravasation, etc. Many of these processes require an interaction between tumor cells and the ECM which constitute an important microenvironmental factor, and depend on the organization of the actin cytoskeleton and the formation of focal adhesions (Liotta et al., 1991; Liotta and Kohn, 2001) . The composition of the ECM surrounding the cells is a key in their behavior, it modulates their ability to proliferate and migrate. Also the morphology of the cells varies greatly depending on the composition of the ECM to which they are exposed, but the molecular basis for these dierences are not yet completely understood (Ridley, 2000) .
The interaction with the ECM is primarily mediated by integrins Hynes, 1992) . Among the integrins, those containing the b1 subunit, referred to as VLA integrins, are involved in cell adhesion to the ECM Hynes, 1992) . This group of integrins functions as receptors for major ECM components such as lamin (LN) and ®bronectin (FN) , and are thought to play pivotal role in tumor development and progression. Integrins are physically linked to the actin cytoskeleton and mediate the formation of focal adhesions, which are large protein complexes containing both cytoskeletal and signaling proteins Hynes, 1992) . Integrin clustering initiates an array of signaling cascades, including activation of Rho family small GTP-binding proteins, PI3-kinase, and protein tyrosine kinases (PTKs) such as focal adhesion kinase (FAK), src and c-Abl Parsons, 1996) . Integrin-dependent adhesive interactions are key regulators of numerous complex biological processes, including cell migration, tissue organization, cell growth, blood clotting, in¯ammation, homing and target recognition by lymphocytes, and the dierentiation of many cell types. In several cases, oncogenes speci®cally stimulate integrin pathways, thus supporting a model in which oncogenes induce anchorage independent growth by substituting for cell adhesion (Schwartz, 1997; Frisch et al., 1996) .
One of the key members of the integrin-signaling pathway is FAK. FAK is a non-receptor protein tyrosine kinase that colocalizes with integrins in focal adhesions. It is phosphorylated and activated in response to integrin stimulation and by some oncogenes (Schlaepfer et al., 1999; Parsons et al., 2000) . FAK phosphorylation has been observed on ®ve dierent tyrosine residues: Y397, Y407, Y576, Y577, and Y925 (Schlaepfer et al., 1994; Calalb et al., 1995) , with tyrosine 397 being the major autophosphorylation site. A number of proteins are known to bind to Y397 upon phosphorylation, including c-src, Shc, PI3 kinase and Csk (Cobb et al., 1994; Guinebault et al., 1995; Sabe et al., 1994; Schlaepfer and Hunter, 1997) . PI-3 kinase is also activated upon cell binding to extracellular matrix proteins (Khwaja et al., 1997) and is phosphorylated by FAK in vitro (Chen and Guan, 1994) . FAK is playing an important role in regulating cell survival and growth (Frisch et al., 1996; Gilmore and Romer, 1996) as well as cell migration (Gilmore and Romer, 1996; Ilic et al., 1995; Cary et al., 1996) .
Although FAK does not appear to function as a classical oncoprotein, the central role of FAK in integrin signaling and the involvement of integrins in tumor progression and metastasis suggests that FAK may be a target in the multistep progression towards a malignant phenotype. Increased expression of FAK has been proposed to correlate with increased invasion and migration of several metastatic tumors (Owens et al., 1995; Weiner et al., 1993) including melanomas (Akasaka et al., 1995) . Oncogenes such as v-src have been shown to stimulate FAK phosphorylation (Schwartz, 1997; Kanner et al., 1990) , and to cause increased FAK activity towards its substrates (Guan and Shalloway, 1992) , suggesting that the activity of FAK rather than its expression level is altered in cancer. Thus potential links between oncogenes and integrin-signaling pathways involving FAK have been observed. However, the mechanism of FAK function and the role it plays in tumorigenesis has yet to be determined. Melanoma cells show marked dierences in aggressiveness, cell migration rate, and organization of actin stress ®bers (Frisch et al., 1996) . Dierences in migration rate among various melanoma cell lines can be greater than 10-fold (Parsons, 1996) . High migration rate usually re¯ects the metastatic potential of the cells and is greatly aected by the interaction of the cells with dierent ECM components.
In the present study we asked whether FAK disregulation might contribute to the malignancy of human melanoma. We used human melanoma cell lines with dierent degree of malignancy and compared their behavior following adhesion to ®bronectin, to that of premalignant nevus and to neuroblastoma cell lines. In order to study changes solely attributed to dierences in the malignant phenotype of the cells rather than to genetic variations between patients, we studied three pairs of adherent cell lines, each pair included local and metastatic cells taken from the same patient. The results obtained with these melanoma cells have been con®rmed by using other melanoma cell lines, with various degrees of malignancy, taken from dierent patients. We show that in melanoma and not in nevus or in neuroblastoma cells, FAK exhibits various degrees of constitutive phosphorylation. In those cells where the constitutive activation of FAK is low there is a marked additional increase in its activation level following incubation on FN. However, in those cells where the constitutive activation of FAK is high, there is only a slight further increase in its activation level following incubation on the substrate. Our experiments thus demonstrate that in melanoma cells there is neither an increase in the amount of FAK nor in its phosphorylation capacity, but rather in its levels of constitutive activation. We further show that FAK constitutive activation is regulated by the cytoskeleton. These results suggest that steps along the integrinsignaling pathway involving FAK might participate in the regulation of the acquired ability of melanoma cells to invade and metastasize.
Results
The results obtained from cells from two groups of melanoma patients are presented. The ®rst group includes three patients ± MEL1, 2, and 3. From MEL1 a nevus and a metastatic cell line have been derived, and from each of the other two, MEL2 and MEL3, a primary and a metastatic cell line have been established. This group enables to detect changes solely attributed to dierences in the malignant phenotype of the cells rather than to genetic variations between patients. The other group consists of eight melanoma cell lines, with various degree of malignancy, taken from dierent patients. Two additional hyperplastic nevus cell lines, developed from yet two other patients, as well as three neuroblastoma cell lines were studied for comparison. Nevus cell lines are equivalent to cells from benign tumor.
It is noted that all cells used in this study are not widely used cell lines kept in culture inde®nitely. Rather, these are newly developed cell lines originating from primary tumors that were frozen after few passages. These lines were reintroduced to culture especially for our investigation and used until passage 15 ± 20.
Adhesion to fibronectin
Adhesion to FN is primarily mediated by a5b1 (VLA5) and also by a4b1 (VLA4) and a3b1 (VLA3). The expression level of these integrins on the cells was determined by¯ow cytometry. Over 95% of the nevus as well as the melanoma cells expressed these integrins, however the mean¯uorescence of VLA4 and 5 of the melanoma cells was lower than that of the nevus (Table 1) , no dierence was found between primary and metastatic cells. Similarly, Western blot analysis (Figure 1 ) revealed that the level of the integrin b1-subunit in all melanoma cell lines was lower than in nevus cells. The TS2/16 anti-b1 antibody used for the Western blots recognizes a broad band around 130 kDa or around 115 kDa when run in non-reduce conditions. In some cells this band appears alone and in others it appears together with higher or lower molecular weight bands, but it is not clear if the other bands are directly recognized by the antibody or merely associated with the main band (Hemler et al., 1983 (Hemler et al., , 1984 .
Analysis of the kinetics of cell adhesion to FN ( Figure 2 ) showed that all tumor cells adhered to the substratum faster than nevus cells in spite of the fact that they expressed lower levels of the relevant integrins. Thus, nevus cells reached 100% adherence to FN after 6 h of incubation, whereas tumor cells reached maximum adherence after 1 ± 3 h. Interestingly, the two primary tumor cell-lines showed a delay in adherence to FN as compared to the metastatic cell lines ± only 30% of the primary cells vs around 50% of the metastatic cells adhered and started to spread out by 15 min (Figure 2 ). These results suggested to us that steps along the integrin-signaling pathway are constitutively active in melanoma cells and that this activation might correlate with tumor progression. Activated integrins could promote rapid adherence, and migration of the cells.
FAK is constitutively active in melanoma cells
To see whether FAK is altered in melanoma, we ®rst compared the amount of FAK protein in cell lysates in reference to the amount of GAPDH in the cells. As seen in Figure 3a , the nevus as well as adherent melanoma cells (MEL1, MEL2, and MEL3) with dierent degree of malignancy, expressed similar amounts of FAK. This has been con®rmed with eight additional melanoma cell lines (not shown).
The phosphorylation pattern of FAK following adhesion to FN as a function of time was then studied. To eliminate background phosphorylation of FAK, the cells were starved overnight in minimal medium containing 0.5% serum and then kept in suspension in serum free medium for 2 h prior to the onset of the experiments. The results show a dramatic dierence between melanoma and the other cells tested (Figures 3b, c, and 4a ± c) . In all melanoma but not in nevus or in neuroblastoma cells used as controls, FAK exhibited signi®cant levels of phosphorylation when in suspension (time 0) (Figure 3b ,c), implying that FAK is constitutively active in melanoma cells. From our results with primary and metastatic cells taken from the same patients (Figure 3b ), it appears as if the level Figure 1 Expression level of Integrin b1 subunit. Western blot analysis of integrin b1 subunit in whole cell lysates. The three nevus cell lines were taken from three dierent patients. MEL2 and MEL3 are two dierent patients. P: primary tumor; M: metastatic tumor. The amount of protein in the lanes was veri®ed by probing the amount of GAPDH in the lanes. The integrin b1 subunit is marked as a band around 115 kDa and GAPDH as a 36 kDa band Figure 2 Kinetics of adhesion to FN of nevus and melanoma cells. Prior to the onset of the assay cells were incubated overnight in starvation medium containing 0.5% serum, and then trypsinized and kept in suspension for 2 h in serum free medium containing 0.5% BSA. MEL2 and MEL3 are two dierent melanoma patients. P: primary tumor; M: metastatic tumor of FAK constitutive activation is higher in more malignant cells, however this needs further substantiation with many more cases. When cells were replated on FN, nevus cells exhibited the slowest kinetics of phosphorylation as compared to all other cells tested ( Figure 4a) . Furthermore, the kinetics of FAK activation in MEL3 cells (Figure 4c ), the most aggressive phenotype (Berger et al., 1994) , was dierent from that of nevus and of other melanoma cells tested (MEL1 and MEL2) (Figure 4a,b) . In MEL3 cells, FAK phosphorylation reached a plateau and even started to level o after 30 min on FN. At ®rst it seemed that the kinetics of FAK phosphorylation in nevus and MEL1 and MEL2 melanoma cells was similar ± the phosphorylation kept increasing as a function of time on FN and did not reach a plateau even after 60 min. However, analysing the rate of FAK phosphorylation (i.e. phosphorylation in`time x' over the amount of FAK in`time x') revealed a dierent kinetics pattern. In those cells where the constitutive activation of FAK was low, the rate of increase in FAK PY as a function of time was high (8 ± 9-fold in Nevus and 10 ± 11-fold in the primary tumor of MEL2). As the constitutive activation of FAK increased, the rate of its further phosphorylation as a function of time on FN was lower. Thus, in MEL1 metastatic cells, where the PY level in time 0 was higher than in nevus cells, the rate of PY increase following 60 min on FN was only fourfold as compared to around eightfold in MEL1 nevus cells. Similar dierence can be observed between primary (fourfold increase) and metastatic MEL2 cells (10-fold increase). On the other hand, in MEL3 cells that are highly malignant, the constitutive activation of FAK was robust and further activation could hardly be achieved. Thus, it seems that in melanoma cells there is neither an increase in the amount of FAK nor in its phosphorylation capacity, but rather in its levels of constitutive activation.
FAK activation is regulated by the cytoskeleton
Is FAK itself disregulated in melanoma or steps along the integrin-signaling pathway upstream of FAK are responsible for its disregulated activity? Since FAK activation is dependent upon the integrity of the Western blot analysis of FAK in whole cell RIPA-lysates. The amount of protein in the lanes was veri®ed in reference to the amount of GAPDH in the lanes. MEL1, MEL2 and MEL3 are three dierent melanoma patients. From MEL1 ± a benign nevus and a metastatic (M) cell line has been derived and from each of the two other patients a primary (P) and a metastatic cell line (M) has been developed (b and c). Anchorage-independent FAK phosphorylation: (b) MEL1, MEL2 and MEL3 are the same patients as for a; (c) Eight melanoma cells with dierent degree of malignancy taken from dierent patients, and as controls ± three neuroblastoma and one nevus cell lines. Cells were starved overnight and 2 h prior to testing were put in suspension in serum free medium. Cells were then lysed with RIPA buer, FAK immunoprecipitated with anti-FAK antibodies, resolved on SDS ± PAGE and blotted with anti-PY antibodies. The membrane was then stripped and blotted with anti-FAK antibodies. The FAK protein is marked as a 125 kDa band and GAPDH as a 36 kDa band cytoskeleton (Needham and Rozengurt, 1998; Schlaepfer et al., 1999) , we looked to see whether in melanoma cells, like in other adherent cells, FAK is regulated by the cytoskeleton. To this end adherent and suspended cells, were treated with Cytochalasin-D to disrupt actin ®laments, and FAK phosphorylation was then assessed (Figure 5a) . Indeed, Cytochalasin-D reduced the level of FAK phosphorylation in adherent melanoma. It also blocked almost completely FAK activity in suspended melanoma cells. These results argue that defects in the cytoskeleton or in the cytoskeleton regulation may be responsible at least in part for FAK constitutive activation in melanoma. Our ®ndings that larger amount of FAK was present in the detergentinsoluble fraction of metastatic cells, either adherent or suspended, as compared to that of nevus cells is consistent with this interpretation (Figure 5b) .
To further characterize the role of FAK in melanoma progression, we transfected the cells with the dominant negative form of FAK ± FRNK. Similar to other reports (Xu et al., 1998; Maung et al., 1999) , FRNK transfected melanoma cells detached from the substratum whereas melanoma cells transfected with empty vector did not. Also, the results obtained with cells transfected with empty vector were similar to those with non-transfected cells (not shown). The results with FRNK transfected cells argue that FAK is essential for maintaining the enhanced adhesive phenotype of melanoma cells. However, the complete loss of adhesion in FRNK transfected cells precludes using this approach to test the role of FAK in cell migration and tumorigenicity. On the other hand FAK was found in very low amounts or even completely absent in highly metastatic cells that have lost completely their requirement for adhesion ( Figure 6 ). These cells also do not express the integrin b1-subunit (Figure 6 ), they grow continuously in suspension, and do not become adherent to any of the substrata tested (FN, LN, and vitronectin). Similar results were obtained with a non-adherent population selected from an adherent metastatic cell line (data not shown).
Discussion
In this report we present a study on the activity of FAK in human malignant melanoma cells with dierent degree of malignancy. This is in order to see whether disregulation of the FAK protein contributes to the malignancy of this disease. We analysed primary and metastatic tumor cells originating from the same patients, so that dierences between cells, if detected, will be solely attributed to their malignant state, as well as melanoma cells with dierent degrees of malignancy taken from dierent patient. We compared the results to benign nevus and to neuroblastoma cells.
Our study shows that all melanoma cells adhere faster to FN in spite of the fact that the expression levels of b1-integrin subunit in tumor cells was lower than in nevus cells. This suggested to us that steps along the integrin-signaling pathway might be dis- Figure 4 FAK phosphorylation following adherence to FN of nevus and melanoma cells: Cells were treated as described for Figure 3b and then plated on FN. At the indicated time points cells were harvested and lysed in RIPA buer. Lysates were treated as for Figure 3 . Phosphorylation level was assessed by densitometry in reference to the amount of FAK in the lanes. (a1, b1, and c1) Kinetics of FAK phosphorylation in MEL1, MEL2 and MEL3 cells respectively. (a2, b2, c2) phosphorylation rate, calculated as the ratio between the phosphorylation in`time x' and the amount of FAK in`time x' of cells presented in a1, b1, and c1. The FAK protein is marked as a 125 kDa band regulated in melanoma. In the present study we focused on FAK expression and function. We did not observe either an increase in the amount of FAK nor in its phosphorylation capacity in melanoma as compared to nevus. However, we did observe a dramatic dierence in FAK activation between melanoma cells and nevus or neuroblastoma cells. We show that only in melanoma cells FAK is phosphorylated in an adhesion independent manner, implying that it is constitutively active in this disease. It appears as if the level of FAK constitutive activation is higher in more malignant cells, however this needs further substantiation with many more cases. Several reports implicate FAK in the malignancy of human tumors. They argue that the invasiveness and metastatic potential of human tumors is directly proportional to the level of FAK expression (Agochiya et al., 1999) . On the other hand genomic microarray analysis of human metastasis (Clark et al., 2000) and of dierent subgroups of human melanoma (Bittner et al., 2000) have recently revealed enhanced expression of several genes, some of them are involved in extracellular matrix assembly and in the actin-based cytoskeleton. However FAK was not one of those genes, implying that the mechanism by which FAK may be involved in tumorigenesis is not by Figure 6 Expression level of integrin b1 subunit and FAK in highly metastatic melanoma cells that grow non-adherent: Cells from primary tumor that grow adherent (P) and highly metastatic cells that grow in suspension (M) have been derived from patient #1. Another highly metastatic cell-line (M) has been derived from Patient #2. The expression level of b1-subunit and FAK proteins was assessed using Western blot analysis. The amount of protein in the lanes was veri®ed in reference to GAPDH. The integrin b1 subunit is marked as a band around 115 kDa, the FAK as a 125 kDa band and GAPDH as a 36 kDa band Figure 3b either kept in suspension or plated on FN for 2 h were lysed with 1% NP-40. The fraction insoluble in 1% NP-40 was then solubilized in sample buer and resolved on SDS ± PAGE as above. The amount of FAK was assessed by densitometry in reference to the amount of actin in the lanes. The FAK protein is marked as a 125 kDa band and actin as a 42 kDa band overexpression but rather by disregulated activity. A role for FAK constitutive activation in cell transformation has been previously suggested. For example, oncogenic transformation of cells, which abolishes the requirement for anchorage-dependent growth, activates FAK (Guan and Shalloway, 1992) . Also, introduction of constitutively active FAK leads to cell transformation, anchorage-independent growth, and the suppression of apoptosis, thus serving as survival signal for the cells (Frisch et al., 1996) . Those results were obtained from experimental systems whereas our results con®rm these ®ndings in human tumors.
The mechanism by which FAK constitutive activation may contribute to cell migration and metastasis formation is unclear yet. But it may be similar to the situation described for FAK+/+ cells (Ren et al., 2000) . In FAK+/+ cells focal adhesions are rapidly assembled and disassembled, and are regulated by RhoA. A support to this interpretation comes from our experiments in melanoma in which disruption of the actin cytoskeleton and focal adhesions by cytochalasin-D inhibited, although not completely, FAK phosphorylation. Thus our results suggest that defects in the cytoskeleton or in the cytoskeleton regulation are responsible at least in part for FAK constitutive activation. It is consistent with Rho being upstream of FAK (Flin and Ridley, 1996; Ren et al., 2000; Schwartz and Shattil, 2000) , and raises the possibility that Rho is also participating in the malignancy of melanoma. This implies that steps along the integrinsignaling pathway including the cytoskeleton and FAK contribute to the malignancy of human melanoma. This is currently under investigation in our laboratory.
As mentioned above we tried to study the role of FAK in melanoma migration by transfecting melanoma cells with the C-terminal, non-catalytic domain of FAK termed FRNK (Richardson et al., 1997; Nolan et al., 1999) . It has been shown that overexpression of FRNK inhibited tyrosine phosphorylation of FAK and delayed cell spreading on FN (Richardson et al., 1997) . However, in our experiments, like in several other studies on human tumors (Xu et al., 1998; Maung et al., 1999) , the FRNK transfected melanoma cells have detached from the substratum whereas nevus cells did not. Thus, this approach was not applicable for our study. Interestingly, highly metastatic melanoma cells that normally grow in suspension express very little FAK and integrin-b1 subunit. Maung et al. (1999) have also seen very little FAK in 1 melanoma cell line derived from peripheral blood and grows predominantly in suspension. These results suggest that FAK is required for tumor cell adhesion, and that FAK and integrin activation are features of early or intermediate cancer cells. Further progression can lead to a completley anchorage independent phenotype where these signals are no longer required.
It is agreed that FAK binds either directly or indirectly to the b1 integrin cytoplasmic domain and this interaction is required for the recruitment of FAK to integrin clusters (Lewis and Schwartz, 1995) . It is possible therefore, that a mechanism involving FAK and the integrin-b1 subunit contributes to melanoma progression.
Our results taken together imply that pathways involving the actin cytoskeleton and FAK may be among the mechanisms that contribute to the high metastatic potential of melanoma cells.
Materials and methods

Cells and media
Cells from three groups of melanoma patients are presented. The ®rst group includes three patients ± MEL1, MEL2, and MEL3. From MEL1 a preneoplastic nevus and a metastatic (M) cell line have been derived, and from each of the other two, MEL2 and MEL3, a primary (P) and a metastatic (M) cell line have been established. The second group consists of eight melanoma cell lines, with various degree of malignancy, taken from dierent patients.
In addition to the nevus cell line derived from MEL1, two additional hyperplastic nevus cell lines, developed from yet two other patients as well as three neuroblastoma cell lines were studied for comparison. Nevus cell lines are equivalent to cells from benign tumor.
MEL2 and MEL3 cells and all cells from the second group were characterized and established as previously described, (MEL2-P and M is denote VM7, and VM8 respectively; MEL3 ± VM23 and VM31; in the second group ± tumor #1 is denoted VM41, 2 ± VM11, 3 ± VM15, 4 ± VM16, 5 ± VM17, 6 ± VM19, 7 ± VM20, and 8 ± A375) (Berger et al., 1994 (Berger et al., , 1997 . MEL1 cells as well as the two other preneoplastic nevus cell lines were obtained from the oncology department, Hadassa Medical School, Jerusalem, Israel. The melanocytic origin of the cell lines was con®rmed electron microscopically by the presence of melanosomes, immunocytochemically by S 100 and HB 45 antigen detection, and biochemically by melanin and tyrosinase determination (Berger et al., 1994 (Berger et al., , 1997 . The tumorigenicity and the metastatic potential of the cells have been veri®ed in vitro by colony formation in soft agar, and in vivo by tumor formation in nude mice.
The neuroblastoma cell lines were obtained from the Institute of Hemato-oncology, Haim Shiba medical Center, Ramat Gan, Israel.
All cell lines grow adherent and were kept in culture for only 15 ± 20 passages. The melanoma and the neuroblastoma cells were cultured in RPMI containing 10% fetal calf serum (FCS), and the preneoplastic nevus cells in complete medium (20% RPMI, 20% F12-HAM, 30% DMEM, and 30% DMEM containing 25 mM HEPES) containing 10% FCS. The media were supplemented with 2 mM L-gluthamine, penicillin (100 U/ml), streptomycin (100 mg/ml) and nystatin (12.5 U/ml). All tissue culture media, supplements, and solutions were purchased from Biological Industries, Beit Haemek, Israel.
The third group of melanoma included two patients that have been studied for the experiments described in Figure 6 . From patient #1, an adherent primary cell line and a nonadherent metastatic cell line have been established, and from patient #2, only a non-adherent metastatic cell line have been derived. The non-adherent cells grow continuously in suspension and thus do not adhere neither to FN and laminin nor to vitronectin. These cell lines were obtained from the oncology department, Hadassa Medical School, Jerusalem, Israel, and characterized and maintained as above.
Antibodies
The monoclonal anti-human integrins from Serotec Ltd (Oxford, UK) were used for¯ow cytometry at a dilution of 1 : 50. Mouse anti b1 Mab (TS2/16) is a kind gift from Prof MA Schwartz, from the Department of Vascular Biology, The Scripps research Institute. It was used at 1 : 20 for¯ow cytometry, for Western blotting it was used at 1 : 500 and the samples were run in non-reduced conditions. Rabbit polyclonal anti-FAK (SC558, Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA) was used at a dilution of 1 : 1000 for immunoblotting and 1.5 ± 2 mg per sample for IP. Mouse anti-phosphotyrosine (PY) Mab 4G10 clone (Upstate Biotechnology Inc., Saranac Lake, NY, USA) was used at the dilution of 1 : 1000 for immunoblotting. Anti-GAPDH Mab (Chemicon Int., Inc., Temacula, CA, USA) was used at 1 : 1000. Horseradish peroxidase conjugated anti-mouse and anti-rabbit antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA) and used according to the manufacturer's instructions.
Flow cytometry
5610
5 to 10 6 cells were incubated with 50 ml of the relevant antibody diluted as above in DMEM containing 5% FCS and 0.1% sodium azide-FACS medium) for 45 min on ice. Following one wash with PBS the cells were incubated with FITC conjugated secondary antibody for another 45 min on ice, then washed three times with cold FACS medium and resuspended in FACSFlow (Beckton Dickinson, Mountain View, CA, USA) containing 0.1% sodium azide. Samples were analysed using the FACSSort (Beckton Dickinson) and results analysed using the CellQuest program (Beckton Dickinson).
Coating plates
Plates were coated with ECM proteins as previously described (Yron et al., 1999) . Brie¯y, bacteriological plates (Miniplast, Ein-Shemer, Israel) were coated either with human plasma FN (Biological Industries) at 20 mg/ml for 1 ± 2 h at room temperature. Following three washes with PBS, plates were blocked with denatured BSA (10 mg/ml BSA in PBS, denatured at 958C for 10 min) for 1 h at room temperature, and then washed three times with PBS. For BSA, bacteriological dishes were coated with denatured BSA for 1 ± 2 h at room temperature, then washed three times with PBS.
Adhesion assay
Adhesion was assessed as previously described (Lewis et al., 1996) . Cells were plated into FN coated wells of a 96 well plate (2610 4 /wells) for the indicated period of time in serum free medium at 378C. Wells were then washed three times with PBS. In order to estimate the number of adherent cells in the wells, cells were incubated with 200 ml of a solution containing 50 mM sodium acetate, pH 5.0, 0.4% Triton X-100 (Merck), and 3 mg/ml nitrophenylphosphate (No. 104, Sigma) for 1 h at room temperature. After the addition of 50 ml 1 M NaOH to each well, the OD at 405 was determined. Assays were performed in triplicates. A linear range of each cell type was determined prior to performing the assays. Percent adhesion was calculated in reference to the OD obtained from 2610 4 suspended cells.
Cell stimulation
For all tests, cells were starved over-night (ON) in de®cient medium (growth medium containing 0.5% FCS), and on the day of the experiments the cells were harvested using trypsin (0.05%)-EDTA (0.02%) (Biological Industries). Trypsin was neutralized with trypsin inhibitor (Sigma-Aldrich, Israel) (75 mg/ml). Cells were then washed once and in order to eliminate background activation, they were kept in suspension in growth medium containing 0.5% heat inactivated BSA for 2 h.
Cells (5 ± 10610 6 /60 ± 90 mm Petri dish in de®cient medium) were plated into plates coated with FN, and incubated at 378C for the indicated periods of time. Cells incubated in plates coated with 0.1% denatured BSA served as non-adherent control. Where indicated cells either suspended or after 1 h on FN, were treated with 0.5 ± 0.6 mg/ml Cytochalasin D (Sigma) for 2 h. Stimulation was stopped by rapid aspiration of the medium and the addition of ice cold stop buer (see below).
Cell lysis and immunoprecipitation
Cells were washed with ice-cold stop buer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM sodium pyrophosphate, 5 mM EDTA, 5 mM NaF, 2 mM sodium orthovanadate), removed from the plates using cell scraper, and lysed in 700 ml RIPA lysis buer (stop buer containing 1% Nonidet p-40 (NP-40, Sigma), 0.1% SDS, 1% deoxycholate, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl (PMSF, Sigma)) for 15 min on ice. Debris was removed by centrifugation for 20 min at 16 000 g, 48C. Where indicated, cells were fractionated into a fraction soluble in 1% NP-40 and an insoluble fraction. The insoluble fraction was solubilized with buer containing SDS and Glycerol (sample buer) and boiled for 15 min. The total amount of proteins in the lysates was measured using the Bio-Rad protein assay (Bio-Rad Laboratories GmbH, Germany). Lysates were then resolved on SDS ± PAGE, transferred onto nitrocellulose membrane, and the proteins of interest were detected by speci®c antibodies using the Western blot technique and visualized on ®lm using ECL (Amersham Pharmacia Biotech). The amount of the relevant protein in the lanes was estimated by densitometry and the total amount of protein in the lanes was veri®ed by immunoblotting the lower part of the membrane with anti-actin or anti GAPDH antibodies.
For immunoprecipitation, lysates were incubated with the indicated concentrations of the relevant antibodies for 4 h at 48C, followed by incubation with Protein A or G-Sepharose (Pharmacia) beads for 1 h. Precipitates were washed ®ve times with lysis buer containing 1% NP-40, dissolved in SDS sample buer, resolved on SDS ± PAGE, transferred onto nitrocellulose membrane and analysed by immunoblotting as above. To reprobe membranes, the bound antibody was removed by incubating the membrane for 60 min at 708C, in stripping solution (2% SDS, 60 mM Tris-HCl pH 6.8, and 0.5% 2-mercaptoethanol (Sigma)). Bands on immunoblots were quantitated by densitometry. 
